Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

This study examines the overall survival of primary peritoneal cancer (PPC), in those patients who had primary debulking surgery (PDS) followed by six cycles of chemotherapy versus those who had neoadjuvant chemotherapy (NACT). This was a prospective observational study performed at Oxford Gynaecological Cancer Centre, over a 5-year period. Eighty-seven patients were clinically suspected of having PPC. Histology confirmed that 64 of these were PPC, with the balance being tubal in origin. PDS was performed in 31 cases. Although NACT was planned in 56 patients, 4 patients didn't receive NACT and therefore excluded from the survival analysis. The overall median survival was 34 months. However, the 5-year survival was 12%. Survival in the PDS group was 46 months versus 24 months in the NACT (p = .011). The conclusion drawn from this study is that patients affected by PPC, selected for PDS have a greater survival advantage than those who had NACT.

Original publication




Journal article


J Obstet Gynaecol

Publication Date





89 - 92


Gynaecological oncology, carcinoma, fallopian tube, neoadjuvant chemotherapy, primary debulking, primary peritoneal, Adult, Aged, Aged, 80 and over, Carcinoma, Chemotherapy, Adjuvant, Cytoreduction Surgical Procedures, Disease-Free Survival, Fallopian Tube Neoplasms, Female, Humans, Middle Aged, Neoadjuvant Therapy, Peritoneal Neoplasms, Prospective Studies, Survival Analysis, Treatment Outcome, Young Adult